Serious About Serialisation: DCC Vital Selects rfxcel as a EU Falsified Medicines Directive and Serialisation Solution Provider
San Ramon, CA February 21, 2018 – rfxcel Corporation, a customer-focused serialisation and track and trace provider for the Life Sciences industry, announced today that DCC Vital, a manufacturer headquartered in Dublin, Ireland, has selected rfxcel to meet its European Falsified Medicines Directive (EU FMD) serialisation requirements.
As a European manufacturer of pharmaceuticals and medical devices, and a logistics provider in the UK, DCC Vital prides themselves in their ability to deliver solutions that will make a difference to patient care. Over the past 5 years, DCC Vital has more than doubled the scale of their business to create a focused support system for their customers in Europe, and most recently have been gaining an increased presence worldwide. As DCC Vital continues to expand their footprint internationally, the company needed a serialisation platform that could accommodate their diverse product offering, understand the need to keep their customers at the top of their focus, and allow them the flexibility to manage their environment based on their specifications.
“DCC Vital selected rfxcel for 3 reasons,” said Conor O’Shea, DCC Vital’s Head of Information Technology. “First, rfxcel is easy to work with. Throughout the evaluation process, rfxcel was very responsive and provided clear answers to our questions. Second, rfxcel offers a simple pricing model that is straight forward & transparent. Finally, rfxcel offers a customer focused architecture that allows us to manage a validated environment according to our quality standards and schedule.”
Relentless commitment to customer success and continuous innovation ensures that rfxcel’s customers meet their requirements and protect their consumers. “We are seeing a paradigm shift in the industry through recent competitive conversions, due to a lack of personalized attention from vendors.” said Glenn Abood, CEO of rfxcel. “Manufacturers and the entire supply chain desire timely response, support, control, and pricing transparency from their solution providers.”
rfxcel offers fixed bid contracts, which ensures customers a clear insight into their pricing model, which is not the case when contracts are based on time and material bids. “Customers are realizing that compliance with the Falsified Medicines Directive is just the starting point. In digitizing their complex supply chains, they are seeking out partners such as rfxcel who are willing to work with their specific needs and ways of working. We help customers to succeed, without imposing inflexible processes or the frequent changes, risk assessments and re-validations involved with other vendors,” said Mark Davison, Senior Director of Operations Europe.
To learn more about the requirements surrounding EU Falsified Medicines Directive compliance or how to build a reliable and flexible serialisation platform that suits your needs, please visit our website at EU FMD Overview.
For more information contact us:
Herb Wong, VP Marketing
hwong@rfxcel.com
rfxcel.com
About rfxcel:
rfxcel is the leading provider of SaaS-based track and trace solutions. Their platform enables companies to protect patients, comply with regulatory mandates, and gain visibility into their supply chain. rfxcel’s relentless commitment to customer success and continuous innovation ensures that companies can meet today’s requirements and tomorrow’s challenges.
To learn more here: Serialization Software
